XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

Product Information

World Health Organization, “Declaration of Helsinki,” Bulletin of the World Health Organization, vol. 86, no. 8, pp. 577–656, 2008.View at: Google Scholar

Multiple benefits: Specially developed for people who want to control appetite, reduce hunger pangs and regulate food portion sizes Our findings stand in line with results obtained by Wang et al., who demonstrated that okra intake decreased serum and hepatic total cholesterol and triglyceride levels, and enhanced fecal excretion of bile acids in mice [ 46]. In other study, Kahlon et al. showed that okra polysaccharides have strong bile acid binding properties [ 47]. Furthermore, Chen et al. reported that okra powder showed oil-binding capacities and cholesterol adsorption properties [ 48]. Additionally, results from animal study by Han et al. imply that inulin may also possess a fat-binding property besides its known beneficial effect as prebiotic, which contributed to a lower triglyceride and cholesterol levels in rats fed with high fat diet in the experiments [ 49]. Thus, the cholesterol-lowering effect of IQP-AE-103 could possibly be related to the physicochemical properties of both okra and inulin. We understand that not everyone can donate right now, but if you can afford to contribute. Your contributions help us rent servers, add new features, and preservation projects. Furthermore, no change in physical activity was noted by analyzing data from IPAQ-SF. Mean stool frequency did not change significantly in any of the study arms throughout the study. EMA/CHMP/ICH/135/1995 Guideline for Good Clinical Practice E6(R2), The European Medicines Agency, London, UK, 2016.

The resulting plant-based compound reduces dietary fat absorption through gastrointestinal fat binding, and has been shown to bind dietary fat at a level previously only achieved by prescription drugs, but without the undesirable side-effects. 4 XLS Medical Appetite Reducer appetite suppressant and hunger control for a more efficient weight loss Our study has several limitations. One limitation is that it was performed over a short period of only 12 weeks, with no follow-up conducted after the study was finished and no weight maintenance phase after the initial weight loss. As such, the study provides no information about the effects of IQP-AE-103 on long-term weight maintenance and on other obesity-related conditions such as diabetes or cardiovascular disease. In addition, the study included subjects of a wide age range. Although the distribution of different age groups was not substantially different between groups in the current study, it may be helpful to include age as a stratification factor in future study. Changes in gut microbiota composition occur with age [ 52], and it has been shown that altered gut microbiota may be associated with obesity [ 53], since IQP-AE-103 contains fibres and polysaccharides from okra pod and inulin, it is likely that the composition of the intestinal gut microbiota may be positively influenced by the consumption of IQP-AE-103. Hence, analysis of gut microbiota changes in overweight and obese subjects of different age groups may provide additional knowledge regarding the effect of IQP-AE-103. Moreover, appetite sensations in the study were assessed using VAS and rating scales, which were not validated for the specific use to measure changes in a similar study design. Last but not least, self-reporting of dietary intake by study subjects, applied for reasons of practicality, may be a limitation. It is known that factors such as gender and weight status affect subjects’ behavior in reporting energy intake; for example, females tended to underreport compared with males, and increasing weight status was associated with an increase in underreporting of energy intake [ 54]. As such, results obtained in the current study, primarily evaluating weight loss, on IQP-AE-103’s effect on appetite sensations remain exploratory. To evaluate a potential effect of IQP-AE-103 on food/energy intake, quantification of actual calorie intake by recording food consumption at an “ad libitum” lunch may be considered in future studies. Direct comparisons of IQP-AE-103 with other weight loss agents that affect dietary fat absorption such as chitosan, Litramine®, or orlistat are difficult for methodological reasons. Ho et al. reported that there were no significant changes from baseline in body weight after 12 weeks of treatment with chitosan [ 39]. A treatment with Litramine® (a proprietary fibre complex) led to 3.8 kg weight loss after 12 weeks of intake [ 17]. As for orlistat (gastric and pancreatic lipase inhibitor), a study by Anderson et al. reported a 3.05 kg weight loss in overweight subjects after 16 weeks of treatment at 180 mg per day [ 40], whereas at higher dose of 360 mg per day, it caused a body weight reduction of 8.3 kg after 12-week period in obese women [ 41].

EMA/CHMP/311805/2014 Committee for Medicinal Products for Human Use (CHMP), Guideline on Clinical Evaluation of Medicinal Products Used in Weight Management, CHMP, London, UK, 2016.

How to compress PDF?

Institute of Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients), The National Acadamy Press, Washington, DC, USA, 2005. Flattened and prolonged glucose response after every meal: Avoid unexpected spikes in blood glucose levels with this natural blend of dietary fibres In the next step, the weight loss and weight maintenance efficacy of IQP-AE-103 should be evaluated in longer clinical trials. Also, it would be worthwhile to further investigate any positive effect on cardiovascular risk factors associated with obesity, particularly in subjects with elevated blood lipids. For further elucidation of mode of action, an assessment of fecal fat excretion, or postprandial blood lipid changes and potentially gut microbiome study could be considered. 5. Conclusion and Implication At the end of the study, 97.1% of the subjects in the high-dose IQP-AE-103 group and 85.3% in the low-dose group rated the benefits of the treatment as “good” or “very good” compared with 10% in the placebo group. However, investigator rated the benefit as “good” or “very good” for 94.1% and 85.3% of the subjects in high- and low-dose IQP-AE-103 groups, respectively, compared with 6.7% for placebo subjects.

Another finding of this study is that besides weight loss, IQP-AE-103 showed beneficial effects on lipid metabolism. A significantly higher proportion of subjects in the high-dose IQP-AE-103 group experienced a reduction in triglyceride levels at the end of the study compared with placebo. In subjects with higher baseline total cholesterol levels (>6.2 mmol/L), high dose of IQP-AE-103 was shown to significantly reduce total cholesterol and LDL-cholesterol (pre-post change). Therefore, current outcome suggests that long-term treatment with IQP-AE-103 could be beneficial for subjects with elevated blood lipid levels in reducing the risk of cardiovascular disease. In addition, a combination of dehydrated okra pod powder and inulin, the active ingredients in IQP-AE-103, has been shown to be a strong fat-binding agent in an in vitro setting simulating in vivo conditions (data not shown); it also exerts high swelling capacity and significantly enhances solution viscosity. Thus, IQP-AE-103 appears to be a promising natural agent that may help to control calorie intake, decrease absorption of dietary fat, and consequently lead to body weight reduction. Current solutions include Litramine, which was awarded the first Class II medical device certification for a plant-based weight management product in the world, and Tanitol, the first enzyme inhibitor that achieved medical device certification by targeting multiple digestive enzymes. Don't take this product if you are allergic to sulphur-containing products (such as sulfites) or any of the ingredients listed. If you experience any allergic symptoms, such as skin rashes or difficulty in breathing or any other side effects, please consult your doctor immediately. Clinically proven efficacy: Promote weight loss through a reduced food consumption - prevent unnecessary snaking and hunger pangsTrademark Elite is run by highly experienced trademark counsel who provide personalized attention and outstanding client service.